Product Description
Tovetumab (MEDI-575) is a fully human IgG2_ monoclonal antibody that specifically binds to human platelet-derived growth factor receptor alpha (PDGFR_) and blocks receptor signal transduction by PDGF ligands. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33210183/)
Mechanisms of Action: PGFR Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Glioblastoma|Non-Small-Cell Lung Cancer
Phase 1: Oncology Solid Tumor Unspecified|Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CD-ON-MEDI-575-1031 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2013-09-11 |
2020-12-24 |
||
| 2010-023854-35 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2013-07-10 |
2022-03-13 |
Treatments |
|
| D2840C00001 | P1 |
Completed |
Hepatocellular Carcinoma |
2012-11-01 |
2019-03-19 |
Treatments |
|
| CD-ON-MEDI-575-1042 | P2 |
Completed |
Glioblastoma |
2012-11-01 |
2019-03-19 |
Treatments |
|
| MEDI-575 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2012-01-19 |
2019-03-18 |
Treatments |
|
| JapicCTI-101129 | P1 |
Completed |
Hepatocellular Carcinoma |
None |